正海生物上半年净利4648.57万元，同比下降45.97%

Core Insights - The company, Zhenghai Biological, reported a revenue of 188 million yuan for the first half of 2025, representing a year-on-year decline of 5.14% [1] - The net profit attributable to shareholders was 46.49 million yuan, down 45.97% compared to the previous year [1] Business Overview - The main business of the company focuses on the research, production, and sales of biological regenerative materials [1] - The company has established a comprehensive business platform that includes research and development, clinical trials, registration, production, quality assurance, and sales [1] - As of now, the company has received approval for 13 medical device products, of which 9 are classified as Class III medical devices [1] - The products are widely used in various medical fields, including oral and maxillofacial surgery, neurosurgery, orthopedics, and dermatology [1]